Hematology Xagena
Acalabrutinib ( Calquence ) is a next-generation, highly selective, covalent Bruton tyrosine kinase inhibitor approved for patients with chronic lymphocytic leukemia ( CLL ) including those with relap ...
T cells expressing anti-CD19 chimeric antigen receptors ( CARs ) can cause complete remissions of relapsed lymphoma. The first clinical trial of anti-CD19 CAR T cells was conducted to show respons ...
Immunochemotherapy is standard of care for patients with previously untreated advanced stage follicular lymphoma ( FL ). Four-year data from the phase III GALLIUM study have previously demonstrated ...
Ibrutinib ( Imbruvica ) has shown single-agent activity in relapse / refractory ( R/R ) primary central nervous system lymphoma ( PCNSL ), and the high dose Methotrexate ( HD-MTX ) has been the backbo ...
The safety and efficacy of Ibrutinib ( Imbruvica ), a once-daily Bruton's tyrosine kinase inhibitor, in chronic lymphocytic leukemia / small lymphocytic lymphoma ( CLL/SLL ) was demonstrated in this ...
According to results from a phase I/IIa trial at The University of Texas MD Anderson Cancer Center, treatment with cord blood-derived chimeric antigen receptor ( CAR ) natural killer ( NK )-cell thera ...
Researchers have evaluated early disease progression and its impact on overall survival ( OS ) in previously untreated follicular lymphoma patients in GALLIUM, and investigated the effect on early dis ...
RESONATE-2 is a phase 3 study of first-line Ibrutinib ( Imbruvica ) versus Chlorambucil in chronic lymphocytic leukemia ( CLL ) / small lymphocytic lymphoma ( SLL ). Patients aged greater than or ...
The majority of patients with chronic lymphocytic leukemia ( CLL ) are older and have multiple comorbidities, including other cancer diagnoses. These patients are routinely excluded from participation ...
The results from the phase 3 ADMIRAL clinical trial comparing Gilteritinib ( Xospata ) to salvage chemotherapy in adult patients with relapsed or refractory acute myeloid leukemia ( AML ) with a FLT3 ...
Data from the CLL14 trial, the first randomized clinical trial to examine stopping an oral-based, chemotherapy-free combination after 12 months in previously untreated patients with chronic lymphocyti ...
Research from Rutgers Cancer Institute of New Jersey ( Unined States ) has shown improved overall survival at five years for pediatric patients with early-stage Hodgkin lymphoma when treated with chem ...
Patients assigned to Gilteritinib ( Xospata ) were found to have a 36% reduction in risk of death compared with those assigned to standard chemotherapy. Median overall survival was 9.3 months for tho ...
Acute myeloid leukemia ( AML ) remains a highly resistant disease to conventional chemotherapy, with a median survival of only 4 months for relapsed and/or refractory disease. Molecular profiling b ...
The European Commission ( EC ) has approved Kymriah ( Tisagenlecleucel, formerly CTL019 ). The approved indications are for the treatment of pediatric and young adult patients up to 25 years of age wi ...
